Trading Halt
Released
Released
Announcement PDF
Market Announcement
23 August 2023
Avecho Biotechnology Limited (ASX: AVE) – Trading Halt
Description
The securities of Avecho Biotechnology Limited (‘AVE’) will be placed in trading halt at the request of AVE,
pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt
until the earlier of the commencement of normal trading on Friday, 25 August 2023 or when the
announcement is released to the market.
Issued by
Melissa Kostopoulos
Adviser, Listings Compliance
23 August 2023
ASX Limited
Market Announcement 1/1
ASX Customer Service Centre 131 279 | asx.com.au
ASX Announcement
23 August 2023
ASX Market Announcements
ASX Limited
Level 4
525 Collins Street, Rialto, North Tower
Melbourne VIC 3000
By email only: melissa.kostopoulos@asx.com.au
tradinghaltsmelbourne@asx.com.au
Dear Melissa,
REQUEST FOR TRADING HALT
Avecho Biotechnology Limited (ASX: AVE) (the Company) requests an immediate halt to the
trading of the Company’s ordinary shares quoted on the Australian Securities Exchange (ASX) in
accordance with ASX Listing Rule 17.1.
The trading halt is requested pending the release of information by the Company to the market
regarding a capital raising (purpose).
In accordance with ASX Listing Rule 17.1, the Company provides the following information in
relation to the request:
1. The trading halt is necessary to assist the Company in managing its continuous disclosure
obligations as the Company expects to make a material announcement to the market in relation
to the stated purpose above.
2. The Company requests that the trading halt remains in place until the earlier of commencement
of normal trading on Friday, 25 August 2023, or when the announcement regarding the stated
purpose is released to the market.
3. The Company expects to make the announcement to the market before the commencement of
normal trading on Friday, 25 August 2023.
4. The Company is not aware of any reason why the trading halt should not be granted or of any
further information necessary to inform the market about the trading halt.
Please contact me if you require any further information concerning this matter.
Yours sincerely.
Melanie Leydin
Company Secretary
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
About Avecho
Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and
Animal Health products using its proprietary drug delivery system called TPM® (Tocopherol
Phosphate Mixture). TPM® is derived from Vitamin E using unique, proprietary and patented
processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of
drugs and nutrients.
Avecho’s major projects include delivering TPM® enhanced injectable, oral and topical products
for the human health market, including the recently announced application of TPM® to
cannabinoids. The Company is also developing TPM® to enhance feed efficiency and health of
livestock.
See more here - avecho.com.au
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
Share your feedback
Discover